U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Renal interstitial fibrosis

MedGen UID:
68628
Concept ID:
C0235989
Disease or Syndrome
SNOMED CT: Renal interstitial fibrosis (95577005)
 
HPO: HP:0032948

Definition

The accumulation of collagen and related extracellular matrix (ECM) molecules in the interstitium of the kidney. The interstitium is expanded by the presence of collagen that stain blue on trichrome. Tubules are not back to back, but rather separated by fibrosis and can be atrophic. [from HPO]

Term Hierarchy

Conditions with this feature

Nephronophthisis 13
MedGen UID:
482242
Concept ID:
C3280612
Disease or Syndrome
The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Løken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).
Karyomegalic interstitial nephritis
MedGen UID:
766688
Concept ID:
C3553774
Disease or Syndrome
Karyomegalic tubulointerstitial nephritis (KMIN) is a rare kidney disease characterized clinically by onset in the third decade of progressive renal failure. Renal biopsy shows chronic tubulointerstitial nephritis and interstitial fibrosis associated with enlarged and atypical tubular epithelial cell nuclei (summary by Baba et al., 2006).
Nephronophthisis 19
MedGen UID:
863979
Concept ID:
C4015542
Disease or Syndrome
The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Løken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).
Familial juvenile hyperuricemic nephropathy type 1
MedGen UID:
1645893
Concept ID:
C4551496
Disease or Syndrome
Autosomal dominant tubulointerstitial kidney disease – UMOD (ADTKD-UMOD) is characterized by normal urinalysis and slowly progressive chronic kidney disease (CKD), usually first noted in the teen years and progressing to end-stage renal disease (ESRD) between the third and seventh decades. Hyperuricemia is often present from an early age, and gout (resulting from reduced kidney excretion of uric acid) occurs in the teenage years in about 8% of affected individuals and develops in 55% of affected individuals over time.
COACH syndrome 3
MedGen UID:
1755565
Concept ID:
C5436841
Disease or Syndrome
COACH syndrome is classically defined as Cerebellar vermis hypoplasia, Oligophrenia, Ataxia, Colobomas, and Hepatic fibrosis (Verloes and Lambotte, 1989). Brain MRI demonstrates the molar tooth sign, which is a feature of Joubert syndrome. The disorder has been described as a Joubert syndrome-related disorder with liver disease (summary by Doherty et al., 2010). For a general phenotypic description and a discussion of genetic heterogeneity of COACH syndrome, see 216360.
Hepatorenocardiac degenerative fibrosis
MedGen UID:
1808950
Concept ID:
C5676996
Disease or Syndrome
Hepatorenocardiac degenerative fibrosis (HRCDF) is a primarily fibrotic disease affecting the liver, kidney, and heart, with considerable variability in disease onset and expression. Affected individuals develop degenerative hepatic fibrosis in childhood or early adulthood, with variable later onset of fibrocystic kidney disease and hypertrophic cardiomyopathy (Devane et al., 2022).
Polycystic kidney disease 7
MedGen UID:
1823995
Concept ID:
C5774222
Disease or Syndrome
Autosomal dominant polycystic kidney disease (ADPKD) is generally a late-onset multisystem disorder characterized by bilateral kidney cysts, liver cysts, and an increased risk of intracranial aneurysms. Other manifestations include: cysts in the pancreas, seminal vesicles, and arachnoid membrane; dilatation of the aortic root and dissection of the thoracic aorta; mitral valve prolapse; and abdominal wall hernias. Kidney manifestations include early-onset hypertension, kidney pain, and kidney insufficiency. Approximately 50% of individuals with ADPKD have end-stage kidney disease (ESKD) by age 60 years. The prevalence of liver cysts increases with age and occasionally results in clinically significant severe polycystic liver disease (PLD), most often in females. Overall, the prevalence of intracranial aneurysms is fivefold higher than in the general population and further increased in those with a positive family history of aneurysms or subarachnoid hemorrhage. There is substantial variability in the severity of kidney disease and other extra-kidney manifestations.

Professional guidelines

PubMed

Liu SJ, Cao YL, Zhang C
Molecules 2024 Feb 27;29(5) doi: 10.3390/molecules29051029. PMID: 38474541Free PMC Article
Liu Y, Su YY, Yang Q, Zhou T
Stem Cell Res Ther 2021 Jun 10;12(1):333. doi: 10.1186/s13287-021-02391-w. PMID: 34112221Free PMC Article
Kovesdy CP, Kopple JD, Kalantar-Zadeh K
Am J Clin Nutr 2013 Jun;97(6):1163-77. Epub 2013 May 1 doi: 10.3945/ajcn.112.036418. PMID: 23636234Free PMC Article

Recent clinical studies

Etiology

Dong Z, Chen F, Peng S, Liu X, Liu X, Guo L, Wang E, Chen X
Front Endocrinol (Lausanne) 2023;14:1207444. Epub 2023 Nov 8 doi: 10.3389/fendo.2023.1207444. PMID: 38027143Free PMC Article
Tao Y, Tang C, Wei J, Shan Y, Fang X, Li Y
Mol Med 2023 May 9;29(1):63. doi: 10.1186/s10020-023-00657-y. PMID: 37161357Free PMC Article
Xu S, Yang X, Chen Q, Liu Z, Chen Y, Yao X, Xiao A, Tian J, Xie L, Zhou M, Hu Z, Zhu F, Xu X, Hou F, Nie J
EBioMedicine 2022 Dec;86:104312. Epub 2022 Nov 4 doi: 10.1016/j.ebiom.2022.104312. PMID: 36335669Free PMC Article
Barroso-Gil M, Olinger E, Sayer JA
Biochem Soc Trans 2021 Jun 30;49(3):1205-1220. doi: 10.1042/BST20200791. PMID: 33960378
Sánchez-Lozada LG, Tapia E, Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J
Semin Nephrol 2005 Jan;25(1):19-24. doi: 10.1016/j.semnephrol.2004.09.004. PMID: 15660330

Diagnosis

Niu X, Xu C, Cheuk YC, Xu X, Liang L, Zhang P, Rong R
J Transl Med 2024 Feb 20;22(1):186. doi: 10.1186/s12967-024-04971-9. PMID: 38378674Free PMC Article
Xiang X, Zhu J, Dong G, Dong Z
Front Immunol 2022;13:861498. Epub 2022 Apr 8 doi: 10.3389/fimmu.2022.861498. PMID: 35464484Free PMC Article
Barroso-Gil M, Olinger E, Sayer JA
Biochem Soc Trans 2021 Jun 30;49(3):1205-1220. doi: 10.1042/BST20200791. PMID: 33960378
Svenningsen P, Hinrichs GR, Zachar R, Ydegaard R, Jensen BL
Pflugers Arch 2017 Nov;469(11):1415-1423. Epub 2017 Jun 27 doi: 10.1007/s00424-017-2014-y. PMID: 28656379
Farris AB, Colvin RB
Curr Opin Nephrol Hypertens 2012 May;21(3):289-300. doi: 10.1097/MNH.0b013e3283521cfa. PMID: 22449945Free PMC Article

Therapy

Zhu X, Lu J, Rao J, Ru D, Gao M, Shi D, Cao K, Wen S, Dai C, Wang X, Mi W, Liu L, Zhou H
Am J Pathol 2023 Aug;193(8):1029-1045. Epub 2023 May 24 doi: 10.1016/j.ajpath.2023.05.002. PMID: 37236504
Xiang X, Zhu J, Dong G, Dong Z
Front Immunol 2022;13:861498. Epub 2022 Apr 8 doi: 10.3389/fimmu.2022.861498. PMID: 35464484Free PMC Article
Zhang L, Huang C, Fan S
Biofactors 2021 Jan;47(1):59-68. Epub 2020 Nov 20 doi: 10.1002/biof.1693. PMID: 33217771
Li R, Guo Y, Zhang Y, Zhang X, Zhu L, Yan T
Int J Mol Sci 2019 Mar 4;20(5) doi: 10.3390/ijms20051103. PMID: 30836660Free PMC Article
Klahr S
Intern Med 2000 May;39(5):355-61. doi: 10.2169/internalmedicine.39.355. PMID: 10830173

Prognosis

Li Y, Chen S, Yang Q, Liu X, Zhou W, Kang T, Wu W, Ou S
J Transl Med 2024 Jul 11;22(1):649. doi: 10.1186/s12967-024-05466-3. PMID: 38992710Free PMC Article
Hua C, Qiu L, Zhou L, Zhuang Y, Cai T, Xu B, Hao S, Fang X, Wang L, Jiang H
Eur Radiol 2023 Aug;33(8):5211-5221. Epub 2023 May 6 doi: 10.1007/s00330-023-09674-1. PMID: 37148348
Xu S, Yang X, Chen Q, Liu Z, Chen Y, Yao X, Xiao A, Tian J, Xie L, Zhou M, Hu Z, Zhu F, Xu X, Hou F, Nie J
EBioMedicine 2022 Dec;86:104312. Epub 2022 Nov 4 doi: 10.1016/j.ebiom.2022.104312. PMID: 36335669Free PMC Article
Barroso-Gil M, Olinger E, Sayer JA
Biochem Soc Trans 2021 Jun 30;49(3):1205-1220. doi: 10.1042/BST20200791. PMID: 33960378
Farris AB, Colvin RB
Curr Opin Nephrol Hypertens 2012 May;21(3):289-300. doi: 10.1097/MNH.0b013e3283521cfa. PMID: 22449945Free PMC Article

Clinical prediction guides

Niu X, Xu C, Cheuk YC, Xu X, Liang L, Zhang P, Rong R
J Transl Med 2024 Feb 20;22(1):186. doi: 10.1186/s12967-024-04971-9. PMID: 38378674Free PMC Article
Ito H, Hirose T, Sato S, Takahashi C, Ishikawa R, Endo A, Kamada A, Oba-Yabana I, Kimura T, Murakami K, Nakamura Y, Takahashi K, Mori T
Hypertens Res 2023 Dec;46(12):2705-2717. Epub 2023 Oct 16 doi: 10.1038/s41440-023-01451-3. PMID: 37845397Free PMC Article
Xu S, Yang X, Chen Q, Liu Z, Chen Y, Yao X, Xiao A, Tian J, Xie L, Zhou M, Hu Z, Zhu F, Xu X, Hou F, Nie J
EBioMedicine 2022 Dec;86:104312. Epub 2022 Nov 4 doi: 10.1016/j.ebiom.2022.104312. PMID: 36335669Free PMC Article
Gao J, Wu L, Zhao Y, Hong Q, Feng Z, Chen X
Exp Cell Res 2022 Jan 15;410(2):112965. Epub 2021 Dec 8 doi: 10.1016/j.yexcr.2021.112965. PMID: 34896075
Xiang E, Han B, Zhang Q, Rao W, Wang Z, Chang C, Zhang Y, Tu C, Li C, Wu D
Stem Cell Res Ther 2020 Aug 3;11(1):336. doi: 10.1186/s13287-020-01852-y. PMID: 32746936Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...